Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide
2. Pf-04554878
3. Vs-6063
1. 1073154-85-4
2. Pf-04554878
3. Vs-6063
4. 1345713-71-4
5. Defactinib (vs-6063, Pf-04554878)
6. N-methyl-4-((4-(((3-(n-methylmethylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide
7. N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
8. 53o87ha2qu
9. Vs 6063
10. Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-
11. Vs6063
12. N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide
13. N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide
14. Defactinib [usan:inn]
15. Unii-53o87ha2qu
16. Defactinib [usan]
17. Defactinib [inn]
18. Defactinib (usan/inn)
19. Pf 04554878
20. Defactinib [who-dd]
21. Gtpl7910
22. Schembl1627234
23. Chembl3137331
24. Bdbm418817
25. Dtxsid901025937
26. Hms3740o13
27. Amy42170
28. Bcp11299
29. Ex-a1037
30. Ex-a1049
31. Mfcd25977806
32. Nsc778364
33. Nsc781450
34. Nsc782549
35. Nsc800089
36. S7654
37. Us10450297, Example 317
38. Us10450297, Example 318
39. Akos026750300
40. Zinc103297739
41. Ccg-269780
42. Cs-3410
43. Db12282
44. Nsc-778364
45. Nsc-781450
46. Nsc-782549
47. Nsc-800089
48. Sb17060
49. Ncgc00386425-06
50. Ncgc00386425-11
51. Ac-35820
52. As-17045
53. Da-34914
54. Da-45890
55. Hy-12289
56. Ft-0706351
57. Ft-0721609
58. J3.502.756d
59. D10618
60. A887883
61. J-690021
62. Q27077009
63. 7kd
64. N-methyl-4-({4-[({3- [methyl(methylsulfonyl)amino]pyrazin-2- Yl}methyl)amino]-5- (trifluoromethyl)pyrimidin-2- Yl}amino)benzamide (317)
65. N-methyl-4-(4-((3-(n-methylmethylsulfonamido)pyrazin-2-yl)methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)benzamide
| Molecular Weight | 510.5 g/mol |
|---|---|
| Molecular Formula | C20H21F3N8O3S |
| XLogP3 | 1.4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 8 |
| Exact Mass | 510.14094222 g/mol |
| Monoisotopic Mass | 510.14094222 g/mol |
| Topological Polar Surface Area | 151 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 804 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Defactinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Defactinib, including repackagers and relabelers. The FDA regulates Defactinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Defactinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Defactinib supplier is an individual or a company that provides Defactinib active pharmaceutical ingredient (API) or Defactinib finished formulations upon request. The Defactinib suppliers may include Defactinib API manufacturers, exporters, distributors and traders.
Defactinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Defactinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Defactinib GMP manufacturer or Defactinib GMP API supplier for your needs.
A Defactinib CoA (Certificate of Analysis) is a formal document that attests to Defactinib's compliance with Defactinib specifications and serves as a tool for batch-level quality control.
Defactinib CoA mostly includes findings from lab analyses of a specific batch. For each Defactinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Defactinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Defactinib EP), Defactinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Defactinib USP).
LOOKING FOR A SUPPLIER?
